Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OSR Holdings ( (OSRH) ) has shared an announcement.
On March 13, 2026, OSR Holdings held an introductory call with a New York-based healthcare analyst during which its CEO inadvertently mentioned non-public business development information about its drug development subsidiary Vaximm and South Korea-based biopharmaceutical company SillaJen. In response, the company has now publicly disclosed the information under Regulation FD to ensure all investors and stakeholders have equal access to the same details.
The disclosure states that Vaximm is in active negotiations with SillaJen for a potential license to Pexa-Vec, an oncolytic immunotherapy in Phase 2 trials for renal cell carcinoma under the U.S. FDA framework, although no binding agreements have been signed. OSR Holdings also revealed very early, exploratory talks about potentially acquiring a controlling stake of about 16% in SillaJen, while stressing that both the licensing discussions and any potential equity transaction are highly preliminary, may not progress to definitive deals, and are being announced solely to comply with fair disclosure rules rather than to signal imminent transactions.
More about OSR Holdings
OSR Holdings, Inc., listed on NASDAQ as OSRH, operates as a holding company with a focus on drug development through its subsidiary Vaximm AG. Vaximm is engaged in biopharmaceutical research, including clinical-stage oncology projects, and participates in global partnerships in areas such as oncolytic immunotherapy for cancer treatment.
Average Trading Volume: 1,403,178
Technical Sentiment Signal: Sell
Current Market Cap: $12.07M
For a thorough assessment of OSRH stock, go to TipRanks’ Stock Analysis page.